View Older Stories View More Recent Stories
-
BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance
-
Wolfe Research Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Morgan Stanley Assumes BioMarin Pharmaceutical Inc. (BMRN) at Overweight
-
BioMarin Pharma (BMRN) Announces Completion of Acquisition of Inozyme (INZY)
-
Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharma (BMRN) Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN at International Society on Thrombosis and Haemostasis 2025 Congress
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
Stifel Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised at Bernstein Following Inozyme Deal
-
TD Cowen Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN) Following Inozyme Deal
-
Evercore ISI on BioMarin (BMRN): 'INZY Acquisition Looks Like a Solid Addition to the Growing and Often Overlooked Enzyme Therapy Biz'
-
Stifel Comments on BioMarin Pharma (BMRN): 'Acquisition of INZY A Strong Strategic Fit for BMRN; The Type of Asset That Offers Value Arbitrage'
-
BioMarin Pharma (BMRN) Announces Acquisition of Inozyme Pharma (INZY) for $4 Per Share
-
BioMarin Pharma (BMRN) Presents New Data for VOXZOGO in Children with Achondroplasia
-
Cantor Fitzgerald Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharma (BMRN) Tops Q1 EPS by 43c
-
Oppenheimer Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Bernstein Recommends Three US Biotech Stocks Amid 'Heightened Regulatory Uncertainty'
-
BioMarin Pharma (BMRN) Announces Positive Pivotal Data for PALYNZIQ in Adolescents with Phenylketonuria
-
Citi Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
How could tariffs shake up the pharma sector?
-
BioMarin Pharma (BMRN) Appoints Timothy P. Walbert to its Board
-
Oppenheimer Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Outperform
-
Cantor Fitzgerald Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BMO Reiterates Outperform on BioMarin Pharmaceutical Inc. (BMRN) as 'Voxzogo Growth Continues'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $126 at Piper Sandler; 'Strong Execution All Around'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $80 at Scotiabank
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $91 at Stifel
-
After-hours movers: Carvana, Klaviyo, NerdWallet, BioMarin Pharma, and more
-
BioMarin Pharma (BMRN) Tops Q4 EPS by 37c ; Offers Guidance
-
Goldman Sachs Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharma (BMRN) Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
-
BMO Capital Highlights Favorite Names for 2025 in Biotech
-
BioMarin Pharma (BMRN) 6K contracts of January 6K puts trade at 60c and 65c
-
Is Trump 2.0 good or bad for healthcare stocks?
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $65 at Baird
-
William Blair Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Market Perform
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $84 at Canaccord Genuity
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $105 at Leerink Partners
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $81 at Citi
-
BioMarin Pharma (BMRN) Tops Q3 EPS by 38c; raises guidance
-
Raymond James Resumes BioMarin Pharmaceutical Inc. (BMRN) at Outperform
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $86 at Barclays
-
Increasing unusual put option volume: EVGO LEVI ASHR EQT BMRN FUTU
-
Goldman Sachs Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Citi Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $78 at Scotiabank
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $90 at Truist Securities
-
Baird Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)

